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The etiologic agent of severe acute respiratory syndrome (SARS) is
a coronavirus (CoV), which is the responsible for the most severe
human disease produced by a CoV (van der Hoek et al., 2004; Weiss
and Navas-Martin, 2005). SARS-CoV emerged in Guangdong province,
China, at the end of 2002 and during 2003 rapidly spread to 32 coun-
tries causing an epidemic of more than 8000 infected people with a
death rate of around 10% (Drosten et al., 2003; Rota et al., 2003). Since
then, only a few community-acquired and laboratory-acquired SARS
cases have been reported (http://www.who.int/csr/sars/en/). Never-
theless, CoVs similar to SARS-CoV have been found in bats distributed
in different regions all over the planet (Chu et al., 2008; Drexler et al.,
2010; Muller et al., 2007; Quan et al., 2010), making the reemergence
of SARS possible.
SARS-CoV is an enveloped virus with a single-stranded positive-
sense 29.7 kb RNA genome, which belongs to Coronavirinae subfamily,
genus β (Enjuanes et al., 2008) (http://talk.ictvonline.org/media/g/vertebrate-2008/default.aspx). Several proteins are embedded within
theSARS-CoVenvelope: spike (S), envelope(E),membrane (M), and the
group speciﬁc proteins 3a, 6, 7a and 7b (Huang et al., 2006, 2007;
Schaecher et al., 2007; Shen et al., 2005). Protected by the viral
envelope, there is a helicoidal nucleocapsid, formed by the association
of the nucleoprotein (N) and the viral genome (gRNA). The CoV
infectious cycle begins when the S protein binds the cellular receptor,
which in the case of SARS-CoV is the human angiotensin converting
enzyme 2 (hACE-2) (Li et al., 2003; Wong et al., 2004), and the virus
enters into the cell. Then, the virus nucleocapsid is released into the
cytoplasm, and ORFs 1a and 1b are translated directly from the gRNA,
generating two large polyproteins, pp1a and pp1ab, which are
processed by viral proteinases yielding the replication–transcription
complex proteins (Ziebuhr, 2005; Ziebuhr et al., 2000). This complex
associates with double membrane vesicles (Gosert et al., 2002; Snijder
et al., 2006) and is involved in viral genome replication and in the
synthesis of a nested set of subgenomic messenger RNAs (sgmRNAs)
through negative polarity intermediaries in both cases (Enjuanes et al.,
2006; Masters, 2006; Sawicki and Sawicki, 1990; van der Most and
Spaan, 1995; Zuñiga et al., 2010). CoV proteins M, S and E are synthe-
sized and incorporated in the endoplasmic reticulum (ER) membrane,
and transported to the pre-Golgi compartment where M protein
recruits S protein and binds E protein (de Haan et al., 1999; Lim and Liu,
2001; Nguyen and Hogue, 1997). In parallel, N protein binds gRNA to
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interaction of N andM proteins during an intracellular budding process
(Narayanan et al., 2000). Assembled virions accumulate in vesicles that
progress through the secretory pathway, and fuse with the plasma
membrane to release viruses into the extracellular media (Tooze et al.,
1987).
CoV E protein is a small integral membrane protein whose se-
quence varies between 76 and 109 amino acids (Arbely et al., 2004;
Raamsman et al., 2000). Based on primary and secondary structure,
the E protein can be divided into a short hydrophilic amino terminal
stretch of between 7 and 12 amino acids, a hydrophobic zone of
around 25 amino acids with an α-helix secondary structure that
constitutes the transmembrane region of the protein, and a carboxy
terminal domain, that comprises the majority of the protein (Torres
et al., 2007). Nevertheless, a variety of E protein topologies have been
described for different CoVs. Mouse hepatitis virus (MHV) and
infectious bronchitis virus (IBV) E proteins expose their carboxy
terminal region towards the cell cytoplasm, whereas the amino
terminal domain is located towards the luminal side of intracellular
membranes for IBV or towards the cytoplasm for MHV (Corse and
Machamer, 2000; Raamsman et al., 2000). Transmissible gastroen-
teritis virus (TGEV) E protein adopts a carboxy terminus luminal,
amino terminus cytosolic conformation (Godet et al., 1992). In the
case of SARS-CoV two alternative topologies have been proposed. In
one of them, the transmembrane region forms a helical hairpin, with
the amino and carboxy termini oriented towards the cytoplasm
(Arbely et al., 2004; Yuan et al., 2006). In the other one, E protein
establishes a single-pass transmembrane conformation with the
carboxy terminal domain oriented towards the luminal side and the
amino terminal domain remaining oriented towards the cytoplasm
(Yuan et al., 2006). Therefore, the precise intracellular topology of
SARS-CoV E protein is still under debate and needs to be clariﬁed.
Only a small fraction of the pool of CoV E protein generated during
infection is incorporated in virions (Maeda et al., 2001; Raamsman
et al., 2000), which suggests an important role of E protein within the
cell. Apparently, CoV E protein is mainly distributed in intracellular
membranes between ER and Golgi compartments (Lim and Liu, 2001;
Nal et al., 2005; Raamsman et al., 2000), where it participates in virus
assembly, budding and intracellular trafﬁcking through a not fully
understood mechanism. In the case of SARS-CoV, it has been shown
that E protein is located in the ER or in the Golgi apparatus using cells
expressing tagged versions of the protein (Liao et al., 2006; Nal et al.,
2005), however, no studies have been performed using infected cells.
Recently it has been reported that E protein displays ion channel
activity in the plasmamembrane when expressed in mammalian cells
(Pervushin et al., 2009), which indirectly suggests the presence of
SARS-CoV E protein on the cell surface. These data reinforce the need
to clearly determine the subcellular location of SARS-CoV E protein in
infected cells and speciﬁcally, to clarify whether this protein is located
at the plasma membrane.
Different requirements of E protein for virus production have been
described among different CoVs. TGEV (an α genus CoV) E protein is
essential for the maturation and secretion of recombinant infectious
viruses (Ortego et al., 2007, 2002). In contrast, a recombinant MHV (β
genus CoV) lacking E gene was infectious although it showed lower
titers in cell culture than the recombinant wild type virus (Kuo and
Masters, 2003). Similarly, in the case of SARS-CoV, the E gene is not
essential, although recombinant SARS-CoV lacking the E gene (rSARS-
CoV-ΔE) grew from 20- to 200-fold lower than the wild-type virus
(rSARS-CoV wt) in monkey or human cells, respectively (DeDiego
et al., 2007). In addition, SARS-CoV lacking the E gene was attenuated
in two animal models (DeDiego et al., 2007, 2008; Netland et al.,
2010) indicating that SARS-CoV E gene may be a virulence factor.
Of the CoV E protein activities, the ion channel activity is one of the
most remarkable. Several viral proteins with ion channel activity have
been described for other RNA viruses, such as M2 from inﬂuenza Avirus, p7 from hepatitis C virus, Vpu from human immunodeﬁciency
virus (HIV), or 2B from enterovirus (de Jong et al., 2006; Ewart et al.,
1996; Pinto et al., 1992; Wozniak et al., 2010). Nevertheless, the
relevance of the SARS-CoV E protein ion channel activity and its
possible relationship with virus trafﬁcking and assembly is not known.
In vitro studies using artiﬁcial lipid bilayers showed that HCoV-229E,
MHV, SARS-CoV and IBV E proteins behaved as cation-selective ion
channels (Torres et al., 2007; Wilson et al., 2006, 2004). A recent report
determined that SARS-CoV E protein expressed in mammalian cells,
displayed ion channel activity at the plasma membrane as determined
by whole-cell patch clamp (Pervushin et al., 2009). Nevertheless,
contradictory results have also been reported indicating that SARS-CoV
E protein does not behave as an ion channel at the cell surface (Ji et al.,
2009).
The clariﬁcation of the cellular localization and topologyof the SARS-
CoV E protein is a crucial issue to understand the activities of E protein.
In this article, we report the generation and characterization of
monoclonal and polyclonal antibodies speciﬁc for the SARS-CoV E
protein as essential tools to address E protein subcellular location and
topology. The data presented in this study showed that the SARS-CoV E
protein essentially accumulated in the endoplasmic reticulum-Golgi
intermediate compartment (ERGIC)when expressed both alone or after
SARS-CoV infection. No evidence of E protein presence in the plasma
membrane was found using immunoﬂuorescence, immunoelectron
microscopy or cell surface protein labeling and puriﬁcation. In addition,
whole-cell patch clamp assays revealed decreased current intensity in
the plasma membrane of cells expressing E protein, which is not
compatible with an E proteinmediated voltage gated ion channel at the
cell surface. All thesedata indicated that theEproteinwould carryout its
direct functions from intracellular membranes. By using the speciﬁc
antibodies generated in this work and selective permeabilization of
plasma or intracellular membranes, we propose a topological confor-
mation for SARS-CoV E protein in which this protein spans intracellular
membranes only once, with the E protein amino terminus oriented
towards the lumen of intracellular membranes and the E protein
carboxy terminus exposed towards the cytoplasm.
Results
Generation and characterization of antibodies speciﬁc for SARS-CoV E
protein
To determine the cellular localization and topology of SARS-CoV E
protein, ﬁve independently derived hybridomas producing mAbs
speciﬁc for SARS-CoV E protein were generated. SARS-CoV E protein is
mainly hydrophobic and poorly immunogenic (Fig. 1A). Nevertheless,
in silico analysis of the E protein amino acid sequence revealed the
presence of two regions located in the amino (ENT) and carboxy
terminus (ECT) of the protein with higher probability of inducing an
immune response (Fig. 1A). To obtain mAbs recognizing different
regions of the protein, three pairs of BALB/c mice were each
immunized with afﬁnity chromatography puriﬁed full-length SARS-
CoV E protein expressed in bacteria, or in a baculovirus system, or
with chemically synthesized E protein. Sera from immunized mice
were analyzed by ELISA using the three sources of puriﬁed E protein,
and by immunoﬂuorescence using rSARS-CoV wt-infected Vero E6
cells and cells infected with a recombinant virus lacking E gene
(rSARS-CoV-ΔE) as a negative control. ELISA and immunoﬂuores-
cence assays showed that the sera from all immunized animals
contained antibodies speciﬁc for SARS-CoV E protein (data not
shown). However, three of the six mice (one of each pair), which
developed the highest titers to E protein died or became sick prior to
hybridoma generation. The remaining seropositivemicewere boosted
with the same antigen used in previous immunizations, and sacriﬁced
to collect their spleens to generate hybridomas. Five hybridomas that
produced mAbs positive by ELISA, immunoﬂuorescence and Western
AB
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Fig. 1. Characterization of mAbs speciﬁc for SARS-CoV E protein. (A) E protein sequence is divided into three domains: the amino terminal (N-terminal), the transmembrane and the
carboxy terminal (C-terminal). Gray letters represent hydrophobic amino acids, and black letters indicate hydrophilic amino acids. Jamesson–Wolf antigenic index (DNA-STAR,
Lasergene) is shown below the amino acid sequence. Positive values in the graph represent high antigenicity indexes whereas negative values represent low antigenicity indexes.
The highest antigenic regions of the protein are shown in gray boxes. (B) Immunoﬂuorescences of SARS-CoV-infected Vero E6 cells. Vero E6 cells were grown on coverslips and
infected at an moi of 0.3 with rSARS-CoV wt (wt) or with rSARS-CoV-ΔE (ΔE) as a control. At 24 hpi cells were ﬁxed with 4% paraformaldehyde, and labeled with E protein speciﬁc
antibodies (green). Rabbit polyclonal antibody speciﬁc for E protein (pAb α E) was used as a control. mAbs are numbered from E1 to E5. (C) Western blot analysis of SARS-CoV-
infected Vero E6 cells. Vero E6 cells were infected at an moi of 0.3 with rSARS-CoV wt (wt) or with rSARS-CoV-ΔE (ΔE) as a control. At 24 hpi cell lysates were collected and probed
with mAbs speciﬁc for E protein (E1 to E5) or with a polyclonal antibody used as a control (pAbα E). mAbs isotype is indicated bellowWestern blot results (C). (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
71J.L. Nieto-Torres et al. / Virology 415 (2011) 69–82blot assays were selected andmAbswere puriﬁed by G protein afﬁnity
chromatography. All the selected hybridomas were derived from a
mouse immunized with the SARS-CoV E protein produced in bacteria.
The corresponding puriﬁed mAbs (E1, E2, E3, E4 and E5) speciﬁcally
recognized E protein by immunoﬂuorescence assays on Vero E6 cells
infected with rSARS-CoV wt but did not bind to the control rSARS-
CoV-ΔE infected cells (Fig. 1B). The mAbs showed a staining patternconsistent with a perinuclear distribution of E protein, similar to that
observed with a rabbit polyclonal antibody speciﬁc for E protein (pAb
α E) used as a positive control. Nevertheless, some differences in the
staining could be observed. mAb E5 showed the strongest signal and
the lowest background in the immunostaining (Fig. 1B). Western blot
analysis using protein extracts of rSARS-CoV infected Vero E6 cells
showed that all mAbs and the rabbit pAb speciﬁc for E protein
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tein. mAb E4 showed the strongest binding by Western blot (Fig. 1C).
To analyze the immunoglobulin subclass of each antibody, mAbs were
subjected to an ELISA using speciﬁc secondary antibodies recognizing
the heavy chain of mouse immunoglobulins (IgG1, IgG2a, IgG2b, IgG3
and IgM). Three of the selected mAbs matched to IgG2a isotype and
two to IgG2b isotype (Fig. 1C).
To identify the region of E protein recognized by the mAbs, a
PEPSCAN epitopemappingwas performed. A total of 34 peptides of 10
amino acids covering SARS-CoV E protein full-length sequence were
synthesized on a cellulose membrane. Contiguous peptides had eight
overlapping amino acids. All mAbs recognized the same two con-
secutive peptides L65NSSEGVPDL74 and S67SEGVPDLLV76, represent-
ing the end of SARS-CoV ECT domain, although different staining
intensities for one or the other peptide were observed with the
different mAbs (Fig. 2A). Therefore, these mAbs should recognize the
overlapping peptide S67SEGVPDL74. The E protein speciﬁc polyclonal
antibody used as a positive control recognized the same two peptidesFig. 2. Epitope mapping of SARS-CoV E protein speciﬁc mAbs and pAbs by PEPSCAN. (A) 3
synthesized on a cellulose membrane. The peptides overlapped contiguous peptides by 8 am
polyclonal antibody speciﬁc for E protein (pAb α E) or using the speciﬁc mAbs (E1 to E5). As
speciﬁc for rabbit (G α R HRP) and rabbit secondary antibody coupled to HRP speciﬁc for m
speciﬁc for E protein amino terminal domain (pAb α ENT). As a control, a rabbit speciﬁc secas the mAbs (L65NSSEGVPDL74 and S67SEGVPDLLV76) and, in addition,
three consecutive peptides, N45IVNVSLVKP54, V47NVSLVKPTV56 and
V49SLVKPTVYV58, which are also located in the ECT domain (Fig. 2A).
These results indicated that all the antibodies recognized the end of
the ECT, suggesting that this domainwas themost immunodominant E
protein region.
Since all selected mAbs bound the ECT domain, to perform E
protein topology studies, polyclonal antibodies speciﬁc for ENT
domain were generated. To this end, two rabbits were immunized
with a peptide corresponding to the ﬁrst 19 amino acids of the E
protein (MYSFVSEETGTLIVNSVLC) coupled to an eight branched
polylysine core by a carboxy terminal cysteine. Sera from the two
immunized rabbits bound puriﬁed E protein produced in bacteria,
chemically synthesized E protein, and a peptide containing the ENT
domain of the E protein (MYSFVSEETGTL) in an ELISA test (data not
shown). Immunoﬂuorescence analysis showed a speciﬁc staining of
cells transfected with a plasmid expressing E protein (pcDNA-E) or
rSARS-CoV wt-infected cells but not of cells transfected with the4 peptides of 10 amino acids each covering the full length SARS-CoV E protein were
ino acids. (A) E protein derived peptides were probed by Western blot using a rabbit
controls, primary antibodies were omitted and goat secondary antibody coupled to HRP
ouse (R αM HRP) were used alone. (B) Epitope mapping of rabbit polyclonal antibody
ondary antibody coupled to HRP (G α R HRP) was probed alone.
73J.L. Nieto-Torres et al. / Virology 415 (2011) 69–82empty plasmid or infected with the deletion mutant rSARS-CoV-ΔE
(data not shown). The serum showing the lowest background in
immunoﬂuorescence was analyzed by PEPSCAN epitopemapping. The
rabbit antiserum recognized the ﬁrst three peptides M1YSFVSEETG10,
S3FVSEETGTL12 and V5SEETGTLIV14 in which amino terminal domain
of SARS-CoV E protein is included. Therefore this pAb most likely
recognized the oligopeptide V5SEETG10 (Fig. 2B).
SARS-CoV E protein subcellular localization
The subcellular localization of SARS-CoV E protein was studied in
virus-infected cells and in cells transfected with a plasmid encoding
the E protein (pcDNA-E). Special focus was devoted to the potential
presence of E protein in the plasmamembrane, a place where it might
display ion channel activity, a remarkable function of this protein. To
this end, Vero E6 cells were either infected with rSARS-CoVwt or with
rSARS-CoV-ΔE as a control, or transfected with the pcDNA-E plasmid
or the empty plasmid as a control. Cells were ﬁxed at different hours
post infection (hpi) or transfection (hpt), permeabilized, and the
subcellular localization of E protein was determined by immunoﬂu-
orescence, using the E protein speciﬁc antibodies previously described
and antibodies for the cellular proteins PDI (ER marker), ERGIC53
(ERGIC marker) and cadherin (plasma membrane marker). Confocal
microscopy analysis showed similar patterns of E protein distribution
in transfected and infected cells at different time points (Fig. 3),
suggesting that none of the other viral proteins signiﬁcantly in-
ﬂuenced the subcellular localization of SARS-CoV E protein. At 8 and
16 hpt or hpi E protein mainly colocalized with the ERGIC marker,
whereas essentially no colocalization was observed with the ER (in
some infected cells a reduced number of colocalization points could be
seen), and no colocalization with plasma membrane marker was
detected (Fig. 3 and data not shown). Between 24 and 48 hpt or hpi,
when the cytopathic effect became evident in infected cells, E protein
showed a broader staining pattern in part of the cells (30–40%), which
partially overlapped with ERGIC marker, whereas no colocalization
was observed with the ER, or with the plasma membrane (Fig. 3 and
data not shown). These data showed that SARS-CoV E protein was
mainly accumulated within the ERGIC and was not detected at the
plasma membrane. To further analyze whether SARS-CoV E protein is
present at the plasma membrane, immunoﬂuorescence studies were
also performed using non-permeabilized transfected and infected
cells, in order to better preserve plasma membrane structure, and
antibodies speciﬁc for E protein amino and carboxy terminal domains.
No speciﬁc labeling was detected at the plasma membrane level,
reinforcing the previous observations (see below, in SARS-CoV E
protein topology section).
To complement the studies on the subcellular localizationof SARS-CoV
E protein by immunoﬂuorescence, and to further analyze whether E
protein was located in the plasma membrane, immunoelectron micros-
copy analysis was used to determine the presence of SARS-CoV E protein
in Vero E6 cells infected with rSARS-CoV wt or with rSARS-CoV-ΔE as a
control. E protein speciﬁc mAb E5 was used in the immunostaining with
its corresponding gold-labeled secondary antibody. Gold labeling was
analyzed in the plasmamembrane and near the viral factories of infected
cells. Around 800 gold dots on several micrographs were counted for
either rSARS-CoV wt or rSARS-CoV-ΔE-infected cells, and gold labeling
was referredas golddotsper surfaceunits, considering12 nmthewidthof
the plasma membrane. Differential gold staining was found in the viral
factories of rSARS-CoVwt-infected cells as comparedwith rSARS-CoV-ΔE-
infected cells, whereas no speciﬁc labeling was found at the plasma
membrane as determined by Student's t-test statistical analysis (Fig. 4),
what indicated that SARS-CoV E protein was not present at the plasma
membrane of rSARS-CoV wt-infected cells.
The potential presence of SARS-CoV E protein within the plasma
membrane was further studied by biotinylation and puriﬁcation of cell
surface proteins. To this end, Vero E6 cells were infected with eitherrSARS-CoV wt or rSARS-CoV-ΔE as a control. In parallel, cells were
transfected with either a pcDNA-E or with the empty plasmid as a
control. Plasma membrane proteins were biotin-labeled by incubating
cells with Sulfo-NHS-SS-Biotin. This compound is not internalized into
cells through the plasmamembrane and binds to primary amines of the
proteins exposed in cell surface. Cells were lysed and biotinylated
proteins were puriﬁed by afﬁnity chromatography through a neutra-
vidin Sepharose resin. Cell surface proteins should be biotinylated and
captured (B fraction) whereas intracellular proteins should not be
biotin-labeled and, therefore, should be present in the chromatography
ﬂow through (FT fraction). Complete cell lysates, captured B and ﬂow
through FT fractions were analyzed byWestern blot using an E protein
speciﬁc antibody (Fig. 5). In parallel, antibodies recognizing the
cytosolic protein β-actin, the endoplasmic reticulum luminal protein
GRP78 and the plasma membrane protein cadherin where used as
controls of the biotinylation process. Intracellular proteins β-actin and
GRP78 were only present in cell lysates and FT fractions but not in B
fractions (Fig. 5). In contrast, the plasma membrane protein cadherin
was observed in cell lysates, FT fractions and also in B fractions, as
expected. E protein was detected in cell lysates and FT fractions of
rSARS-CoV wt infected cells and in pcDNA-E transfected cells (Fig. 5),
but it was not found in the B fractions, indicating that E protein was not
biotinylated, suggesting that this protein was not accumulated at the
plasma membrane (Fig. 5).
All together, these data indicated that SARS-CoV E protein is
located intracellularly, mainly in the ERGIC, when expressed alone or
in a SARS-CoV infection. No evidence of E protein presence in the
plasma membrane was found using three complementary assays.
Whole-cell patch clamp assays
To complement and reinforce location studies of E protein in the
plasma membrane, ion channel activity measurements were per-
formed by using whole-cell patch clamp. This technique would
determine any potential increase in ion currents due to the presence
of minor quantities of E protein derived ion channels at the plasma
membrane. HEK-293T cells were mock transfected, transfected with
an empty plasmid or with a plasmid expressing SARS-CoV E protein
(pcDNA-E). At 24 hpt cells were analyzed by the patch-clamp
technique in a whole-cell conﬁguration, which allow to measure
voltage activated currents corresponding to voltage gated ion chan-
nels distributed all over the plasma membrane. Interestingly, control
cells without E protein showed high intensity voltage activated
currents, whereas cells expressing E protein revealed a signiﬁcant
decrease in current intensities (Fig. 6). These data suggested that E
protein was not acting as a voltage gated ion channel present at the
plasmamembrane, because, that being the case, an increase in voltage
activated currents intensity should have been observed in cells
expressing E protein as compared with control cells. This ﬁnding
reinforces our previous conclusion on the absence of E protein within
the cell plasmamembrane. The observed decrease in current intensity
could be due to an indirect effect of E protein on plasma membrane
proteins involved in ion transport. In fact we performed E protein pull
down assays (Fig. 7), and demonstrated the interaction of SARS-CoV E
protein with Na+/K+ ATPase alpha 1 subunit and stomatin, that were
identiﬁed by mass spectrometry with signiﬁcant Mascot scores (301/
80 and 251/70 respectively). Na+/K+ ATPase is the main cellular ion
pump involved in ion homeostasis control (Kaplan, 2002) and
stomatin has been described as an ion channel regulator (Price
et al., 2004). These interactions might be responsible for the decrease in
the intensity of voltage activated currents in cells expressing E protein.
SARS-CoV E protein topology
It has previously been shown that E protein is an integral trans-
membrane protein (Liao et al., 2006). To further analyze the topology
Fig. 3. Subcellular localization of SARS-CoV E protein analysis by immunoﬂuorescence. Vero E6 cells were grown on coverslips and transfected with a plasmid encoding E protein
(pcDNA-E) or infected with rSARS-CoV wt. Cells were ﬁxed with 4% paraformaldehyde at 8 and 24 h post transfection (hpt) or post infection (hpi). (A) Cells were labeled with E
protein (green) or ERGIC53 ERGICmarker (red) speciﬁc antibodies. (B) Cells were labeled with E protein (green) or PDI ERmarker (red) speciﬁc antibodies. (C) E protein was labeled
in green and plasma membrane (cadherin) was labeled in red using speciﬁc antibodies. Nuclei were stained with DAPI in all cases (blue).
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Fig. 3 (continued).
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the ENT or ECT domains were used in immunoﬂuorescence assays on
detergent permeabilized cells. Vero E6 cells transfected with plasmids
expressing E protein or infected with SARS-CoV wt were processed
either without permeabilization, after permeabilizing their plasma
membrane by using digitonin, or after permeabilizing plasma and
intracellular membranes by using Triton X-100. An antibody recog-
nizing the cytoplasmic protein β-tubulin, and another one speciﬁc for
the luminal endoplasmic reticulum protein PDI were used as controls
of permeabilization of the plasma membrane or intracellular mem-
branes. The selective permeabilization of the plasma membrane by
using digitonin led to the detection of SARS-CoV ECT domain in cells
transfected with a plasmid encoding E protein and in SARS-CoV wt-
infected cells (Fig. 8). Under these conditions, the cytosolic protein β-
tubulin was also detected, in contrast to the luminal ER protein PDI
that was not accessible, as expected (Fig. 8). Permeabilization of
plasma and intracellular membranes with Triton X-100 allowed the
detection of SARS-CoV ECT domain, β-tubulin and PDI, as expected
(Fig. 8). These experimentswere repeated several timeswith identical
results indicating that SARS-CoV ECT domainwas exposed towards the
cell cytoplasm. In contrast, SARS-CoV ENT domain was only detected
when transfected or infected cells were permeabilized with Triton X-
100, indicating that this domain must only be exposed towards the
luminal side (Fig. 8). Overall, these data indicated that SARS-CoV E
protein has a topological conformation spanning the intracellular
membranes only once exposing its carboxy terminal domain towards
the cell cytoplasm and the amino terminal domain towards the lumen
of intracellular membranes.Discussion
A polyclonal antiserum speciﬁc for the SARS-CoV E protein amino
terminus, and a set of monoclonal antibodies speciﬁc for the SARS-
CoV E protein carboxy terminus have been generated. Using these
antibodies, SARS-CoV E protein was shown to localize essentially in
the ERGIC when expressed alone or in the context of SARS-CoV
infection. No evidence for the presence of the SARS-CoV E protein at
the plasma membrane has been found by using four complementary
approaches. In addition, a topological model for SARS-CoV E protein in
which E protein spans intracellularmembranes only once and exposes
the amino terminal domain towards the lumen of intracellular
membranes and the carboxy terminal domain towards the cytoplasm
has been proposed.
CoV E protein is involved in virus budding, morphogenesis and
intracellular trafﬁcking and possesses ion channel activity (DeDiego
et al., 2007; Ortego et al., 2007; Wilson et al., 2006). In previous
publications, different authors have proposed alternative cellular
locations (ER, Golgi membranes, and plasma membrane) or topolo-
gies (spanning membranes once or twice) for SARS-CoV E protein
(Liao et al., 2006; Nal et al., 2005; Pervushin et al., 2009; Yuan et al.,
2006). To clarify this point, we focused on the subcellular location and
topology of SARS-CoV E protein in transfected and infected cells.
In this work, using mAbs speciﬁc for the SARS-CoV E protein, and
Vero E6 cells, susceptible to SARS-CoV infection, it was shown that E
protein was mainly located in the ERGIC at early times (8 and 16 hpi
or hpt). Moreover, it was shown that this distribution was extremely
similar when E protein was expressed alone from a DNA plasmid or
Fig. 4. Analysis of SARS-CoV E protein subcellular localization by immunoelectron microscopy. Vero E6 cells were infected with rSARS-CoVwt or rSARS-CoV-ΔE. At 16 hpi cells were
ﬁxed with 4% paraformaldehyde and 0.125% glutaraldehyde, scrapped and pelleted. Pellets were processed and sectioned. (A) Ultrathin cryosections were incubated with mAb E5
and an anti-mouse secondary antibody labeled with 10 nm colloidal gold. PM (plasma membrane), VF (Viral factories). Bars 200 nm. (B) Around 800 gold dots were counted in
several images of rSARS-CoV-ΔE or rSARS-CoVwt-infected cells. Gold labeling is represented as gold dots per surface units (10 μm2) at the plasmamembrane (PM), the viral factories
(VF) and at unspeciﬁc locations (UN) such as the cell nucleus ormitochondrion, which represent the background displayed by the antibody. Statistically signiﬁcant data are indicated
with two asterisks (Student's t-test p-valueb0.01).
Fig. 5. Analysis of SARS-CoV E protein presence at the plasma membrane by cell surface protein biotinylation and puriﬁcation assay. Vero E6 cells were either mock transfected,
transfected with a plasmid encoding E protein (pcDNA-E) or with an empty plasmid as a control (pcDNA), or infected with rSARS-CoV wt (wt) or with rSARS-CoV-ΔE (ΔE) as a
control. Plasma membrane proteins were biotin labeled and cells were lysed. Cell lysates (CL) were incubated with an avidin resin, and biotinylated cell surface proteins were
isolated (B). Non-biotinylated proteins were discarded and eluted in the ﬂow through (FT). CL, FT and B fractions were analyzed by Western blot using antibodies speciﬁc for the
intracellular proteins β-actin and GRP78, the plasma membrane protein cadherin and SARS-CoV E protein.
76 J.L. Nieto-Torres et al. / Virology 415 (2011) 69–82
Fig. 6. Whole-cell patch clamp. HEK-293T cells were mock transfected (Mock), transfected with an empty plasmid (pcDNA) or transfected with a plasmid encoding SARS-CoV E
protein (pcDNA-E). At 24 hpt cells were voltage clamped, and stepped from−160 mV to +140 mV in 20 mV increments with pulses of 40 ms from a resting potential of−40 mV.
Current intensity was plotted against voltage. Currents values weremeasured at 30 ms, standard deviations are shown. Lower panels show examples of original recordings from each
cell type.
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signiﬁcantly affected the subcellular location of E protein. At late
times, (between 24 and 48 hpi or hpt) 30 to 40% of the cells express-
ing E protein showed a broader distribution, possibly involving other
cell compartments apart from the ERGIC, which might correspond to
Golgi modiﬁed membranes, similarly to what has been described
previously (Liao et al., 2006). The accumulation of E protein at the ER
was only found occasionally in infected cells. These data indicated that E
protein did not accumulate within this compartment. In contrast to our
observations, other reports described that SARS-CoV E protein
colocalized with ER and Golgi markers (Liao et al., 2006; Nal et al.,Fig. 7. Identiﬁcation of proteins interacting with SARS-CoV E protein. Vero E6 cell
extracts frommock-infected cells (Mock) or cells infected with rSARS-CoVwt or rSARS-
CoV-EtagCt (E-tag) were used in a double afﬁnity chromatography. Puriﬁed proteins
were detected by using Coomassie blue gels. Bands were excised from gels and
identiﬁed by mass spectrometry. Arrows point Na+/K+ ATPase alpha 1 subunit and
stomatin protein bands.2005). The apparent discrepancies between our results and previous
publications,may be explained by the strength of the expression system
used, by the use of different cell lines, by performing the studies at
different time points and by the use of different tagged versions of E
protein. Nevertheless, in the publications by other authors, E protein
location was not analyzed in cells infected with SARS-CoV, as done in
this paper.
It has been reported that E protein displays ion channel activity in
the plasma membrane of mammalian cells (Pervushin et al., 2009),
which has indirectly suggested that E protein is present on the cell
surface. Nevertheless, neither our results shown in this manuscript nor
other publishedwork (Nal et al., 2005; Yuan et al., 2006) have provided
direct evidence showing the presence of SARS-CoV E protein in the
plasma membrane. In fact, special attention was paid in this study to
analyze whether SARS-CoV E protein was located in the plasma mem-
brane. Immunoﬂuorescence analysis of cells transfected with a plasmid
encoding E protein and SARS-CoV-infected cells, revealed that E protein
did not accumulate at the plasma membrane neither at early (8 and
16 hpt or hpi) nor at late time points (24 and 48 hpt or hpi). In addition,
immunoﬂuorescence using non-permeabilized cells and antibodies
speciﬁc for the amino or carboxy terminal domains of E protein did not
reveal any speciﬁc staining at the cell surface. To reinforce these data
immunoelectron microscopy was performed. E protein was identiﬁed
intracellularly in infected cells, close to viral factories, whereas no
signiﬁcant labeling was observed at the plasma membrane. To further
study the possible presence of E protein in the plasma membrane, cell
surface proteins were biotinylated and isolated. Protein biotinylation
was achieved by using a compound that binds covalently to primary
amines, present in lysines side chain and in the protein N-terminal
amino acid. If SARS-CoV E protein would be displayed in the plasma
membrane, it should expose its amino terminal domain towards the
outside of the cell, taking into account our purposed topological
conformation. No lysine residues are contained within SARS-CoV E
protein amino terminal domain. Nevertheless, the amino group of the
Fig. 8. SARS-CoV E protein topology. Vero E6 cells expressing E protein alone (pcDNA-E) or in an infection context (rSARS-CoV wt) were alternatively processed with no
permeabilization (NP), selectively permeabilizing plasmamembrane by using digitonin or permeabilizing all cell membranes by using Triton X-100. Speciﬁc antibodies were used to
label the E protein carboxy terminal domain (ECT, green), E protein amino terminal domain (ENT, green), the cytosolic protein β-tubulin (red) and the luminal ER protein PDI (red).
Nuclei were stained with DAPI (blue). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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evidence of biotinylated E protein was detected, indicating that E pro-
tein did not accumulate in the plasma membrane.In order to investigate potential ion channel activity due to the
presence of E protein at the cell surface, whole-cell patch clamp assay
was performed as a functional approach to alternatively determine
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protein were acting as an ion channel activated by voltage in the plasma
membrane, an increase in current intensities displayedby cells expressing
E protein, as compared with control cells, would be expected. Interest-
ingly, cells expressingEprotein showedadecreaseof current intensities as
comparedwith control cells not expressing E protein, suggesting that this
protein was not acting as an ion channel at the plasma membrane, and
reinforcing the observation that E protein was not physically located
within the plasma membrane. The fact that E protein decreased ion
currents in the plasma membrane might be explained by an indirect
inﬂuence of E protein on other cellular proteins involved in ion
transport. Recently, in our laboratory, two cellular proteins involved in
ion transport: Na+/K+ ATPase alpha 1 subunit and stomatin, have been
identiﬁed as interacting partners of SARS-CoV E protein. Possibly, these
interactions could lead to partial relocalization of these proteins and
therefore to the observed reduction of ion transport, whichmay explain
decreased voltage activated currents intensity detected by whole-cell
patch clamp assays. Importantly, in agreement with our work, it has
been shown that E protein does not display ion channel activity in a
different experimental system, the plasma membrane of Xenopus
oocytes (Ji et al., 2009) but decreases the levels and activity of human
epithelial sodium channels, affecting ion transport at the plasma
membrane level.
Overall, our results from four complementary approaches strongly
suggest that SARS-CoV E protein did not accumulate at the plasma
membrane during SARS-CoV infection, or when expressed alone,
suggesting that the intrinsic activities of E protein should be displayed
in the inner organelles and that plasma membrane permeabilization to
monovalent ions (Pervushin et al., 2009) or to smallweight compounds in
E protein expressing cells (Liao et al., 2004, 2006; Madan et al., 2008), is
most likelydue to indirect effects. In fact, similar interpretationshavebeen
made for the increased plasma membrane permeability to small weight
compounds by another viral protein with ion channel activity such as
coxsackievirus 2B protein (Cornell et al., 2007; de Jong et al., 2006). This
protein also locates in intracellular membranes, from where it alters
protein trafﬁcking by enhancing endocytosis processes resulting in the
entry of small weight compounds. In other viral systems the intrinsic ion
channel activity of speciﬁc viral proteins such as p7 protein of hepatitis C,
was also restricted to intracellular membranes (Wozniak et al., 2010).
Two alternative SARS-CoV E protein topological conformations have
been suggested. Studies using tagged versions of SARS-CoV E protein,
suggested that this proteinmay have a cytosolic amino terminal domain
and a carboxy terminal domain also facing the cytoplasm, or alter-
natively, in a minor proportion, an amino terminal cytosolic, and
carboxy terminal luminal conformation, in intracellular membranes
(Yuan et al., 2006). These topology models would correspond to the
hairpin or to the single transmembrane pass conformations deﬁned for
SARS-CoV E protein transmembrane domain respectively (Arbely et al.,
2004; Torres et al., 2006). In this work, by using highly speciﬁc anti-
bodies for E protein amino terminal and carboxy terminal domains in
selective permeabilization assays, we have clearly shown that E protein
adopted an amino terminus luminal carboxy terminus cytosolic
conformation in intracellular membranes of transfected and infected
cells. The discrepancies on E protein amino terminus orientation with
previous published data, could be due to the use of amino terminal
tagged versions of E protein, whichmay affect the correct association of
the protein with cell membranes. The model proposed here is only
compatiblewith the single transmembranepassdescribed for SARS-CoV
E protein, but in intracellular membranes.
Materials and methods
Viruses
The recombinant parental virus (rSARS-CoV wt) and a virus that
lacks E gene (rSARS-CoV-ΔE) derived from the Urbani strain, wererescued from infectious cDNA clones and titrated as previously de-
scribed (Almazan et al., 2006; DeDiego et al., 2007). Infections were
performed in biosafety level 3 containment facilities by personnel
wearing positive-pressure air-purifying respirators (HEPA AirMate;
3M, Saint Paul, MN).
Cells
The African green monkey kidney-derived Vero E6 cells were
kindly provided by Eric Snijder (Medical Center, University of Leiden,
The Netherlands). The human embryonic kidney-293T cells (HEK-
293T) were kindly provided by Juan Ortín (CNB, Madrid, Spain).
Cells were grown at 37 °C with an atmosphere of 98% humidity, in
Dulbecco's modiﬁed Eagle medium (DMEM, GIBCO) supplemented
with 25 mM HEPES, 2 mM L-glutamine (SIGMA), 1% non-essential
amino acids (SIGMA) and 10% fetal bovine serum (FBS, Biowhittaker).
Plasmids
The plasmid pcDNA 3.1 (+) was purchased from Invitrogen. The
plasmid pcDNA-E, used to express SARS-CoV E protein, was engineered
by inserting a PCR product containing the open reading frame (ORF) of
SARS-CoV E gene, digested with the restriction endonucleases EcoRI
and XhoI in the same sites of the pcDNA 3.1 (+) plasmid. A kozak
sequence (GCCGCC) was placed immediately before the E protein ATG
start codon, to improve protein translation efﬁciency.
Generation of monoclonal antibodies (mAbs) speciﬁc for SARS-CoV E
protein
Three pairs of BALB/c mice females were respectively immunized
with puriﬁed SARS-CoV E protein from one of the following sources:
recombinant histidine-tagged SARS-CoV E protein, expressed using a
baculovirus system; Escherichia coli puriﬁed E protein, obtained
through the NIH Biodefense and Emerging Infections Research
Resources Repository, NIAID, NIH: NR-4284; or chemically synthe-
sized E protein, which was a gift from Jaume Torres (School of
Biological Sciences, Nanyang Technological University, Singapore).
Mice were immunized with three doses of 100, 50 and 50 μg of one
source of protein at days 0, 21 and 35, respectively. Antigen was
delivered intraperitoneally with complete Freund's adjuvant in the
ﬁrst immunization and with incomplete Freund's adjuvant in the
following ones. Ten days after the last immunization, sera were
analyzed by enzyme-linked immunosorbent assay (ELISA) using
puriﬁed E protein from the three origins and by immunoﬂuorescence
using rSARS-CoV-infected Vero E6 cells. Mice that developed an
antibody response to SARS-CoV E protein were selected and boosted
with two consecutive doses of 40 μg of antigen. Three days later,
animals were sacriﬁced, and spleens were collected and dissociated.
Cell fusion with the murine myeloma cell line X63-Ag8.653 (Kearney
et al., 1979) using the polyethylene glycol method was performed
(Galfre and Milstein, 1981) and hybridomas were generated.
Hybridomas were cultured in 96 multiwell plates using ClonaCell®-
HY medium E (StemCell Technologies) supplemented with 10 μM
azaserine. Ten days after seeding, culture supernatants were analyzed
by ELISA, using the three sources of puriﬁed SARS-CoV E protein, and
by immunoﬂuorescence and Western blot, using SARS-CoV-infected
cells. Hybridomas secreting speciﬁc antibodies were selected and
cloned twice by limit dilution. Supernatants were analyzed 10–
14 days after seeding as described above. mAbs puriﬁcation from
hybridoma culture supernatant was achieved by G protein afﬁnity
chromatography in HiTrap™ Protein G HP columns (GE Healthcare),
and dialyzed against phosphate-buffered saline (PBS). Immunoglob-
ulin subclass was determined by ELISA using speciﬁc antibodies
against heavy chain of mouse immunoglobulins (IgG1, IgG2a, IgG2b,
IgG3 and IgM) (Southern Biotech).
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domain of SARS-CoV E protein
Asyntheticpeptide corresponding to theﬁrst 19 residuesof SARS-CoV
E protein (MYSFVSEETGTLIVNSVLC) was coupled to an eight branched
polylysine core via a carboxy terminal cysteine to prepare multiple
antigenic peptides (MAP) as described (Wilson et al., 2004). Two rabbits
were immunized by Biogenes (Berlin, Germany) with 1, 0.5, 0.25 and
0.25 mgof the coupled peptide at days 1, 7, 14 and 28, respectively. Sera
were collected and evaluated by ELISA, using the three sources of
puriﬁed SARS-CoV E protein described above, and a peptide containing
the amino terminal domain and four amino acids of the transmembrane
domain of E protein (MYSFVSEETGTL). Sera were also analyzed by
immunoﬂuorescence and Western blot using pcDNA-E-transfected or
SARS-CoV-infected Vero E6 cells. Rabbits producing E protein speciﬁc
antibodieswere boostedwith 0.25 mgof coupledpeptide at days 50and
57. Final bleed sera of immunized animals were collected at day 64 and
evaluated as previously described.
Confocal microscopy
Vero E6 cells were grown to 90% conﬂuency on glass coverslips and
infected with rSARS-CoV-ΔE or rSARS-CoV wt at a multiplicity of
infection (moi) of 0.3. Alternatively, Vero E6 cells were grown to 70%
conﬂuency in 1 cm2 wells and transfected with 1 μg of DNA using 1 μl
of Lipofectamine 2000 (Invitrogen) according to the manufacturer's
indications. At the indicated hours post infection (hpi) or post
transfection (hpt), media were removed and cells were washed twice
with PBS and ﬁxed with 4% paraformaldehyde in PBS for 30 min at
room temperature. Then, cells were washed twice with PBS and
permeabilized for 10 min with 0.1% Triton X-100 in PBS. Primary
antibody incubations were performed in PBS containing 10% FBS for
1 h 30 min at room temperature. Immunoﬂuorescencewas performed
using mouse mAbs speciﬁc for E protein (dilution 1:5000), ERGIC53
(dilution 1:200, Alexis Biochemicals), protein disulﬁde isomerase
(PDI, dilution 1:500, Abcam), β-tubulin (dilution 1:200, Sigma) and
cadherin (dilution 1:500, Abcam). Rabbit pAbs speciﬁc for E protein
(Alvarez et al., 2010), E protein amino terminal domain and PDI were
used at 1:2000, 1:1000 and 1:500 dilution, respectively. Coverslips
were washed four times with PBS between primary and secondary
antibody incubations. Alexa 488- or Alexa 546-conjugated antibodies
speciﬁc for the different species (dilution 1:500, Invitrogen) were
incubated for 45 min at room temperature in PBS containing 10% FBS.
Nuclei were stained using DAPI (dilution 1:200, Sigma). Coverslips
were mounted in ProLong Gold anti-fade reagent (Invitrogen) and
examined on a Leica SP5 confocal microscope (Leica Microsystems).
Western blot analysis
Proteinswere resolved by sodiumdodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred toanitrocellulosemembraneby
wet immunotransfer and processed forWestern blotting. The blots were
probed usingmousemAbs speciﬁc for E protein (dilution 1:500), β-actin
(dilution 1:10,000, Abcam), cadherin (dilution 1:1000, Abcam) and
rabbit pAbs against E protein (dilution 1:6000) and GRP78 (1:1000,
Abcam). Horseradish peroxidase-conjugated antibodies against the
different species (dilution 1:40,000, Sigma) and the ImmobilonWestern
chemiluminiscence substrate (Millipore) were used to detect bound
antibodies. Chemiluminiscence was detected by exposure to Agfa X-ray
ﬁlm.
PEPSCAN analysis
SARS-CoV E protein sequence was represented in 34 peptides of 10
amino acids each, which overlapped in 8 amino acids with contiguous
peptides. Peptides were synthesized on a cellulosemembrane using theSPOT technique (Frank, 2002) at the CNB proteomics facility (Madrid,
Spain).Membraneswereprocessed as previously described forWestern
blot assays.
Immunoelectron microscopy
Vero E6 cells were grown to 90% conﬂuency and infected with
rSARS-CoV-ΔE or rSARS-CoV wt at an moi of 1. At 16 hpi, cells were
ﬁxed by adding 1 volume of ﬁxative 2× (4% paraformaldehyde, 0.25%
glutaraldehyde in sodium phosphate buffer [PB] 0.2 M pH 7.2) to the
culture medium for 30 min at room temperature. Medium and
ﬁxative 2× mixture were replaced by a ﬁxative 1× solution (2%
paraformaldehyde, 0.125% glutaraldehyde in PB 0.1 M pH 7.2), and
incubated for 1 h 30 min at 4 °C. Fixative was removed, and cells were
scrapped and pelleted. After washing with PB containing 50 mM
glycine, cells were embedded in 12% gelatine and infused in 2.3 M
sucrose. Mounted gelatine blocks were frozen in liquid nitrogen. Thin
sections were prepared in an ultracryomicrotome (Leica EM Ultracut
UC6/FC6, Vienna, Austria). Ultrathin cryosections were collected with
2% methylcellulose in 2.3 M sucrose. Cryosections were incubated at
room temperature on drops of 2% gelatin in PBS for 20 min at 37 °C,
followed by 50 mM glycine in PBS during 15 min, 10% FBS in PBS
during 10 min and 5% FBS in PBS 5 min. Then, cryosections were
incubated with SARS-CoV E protein speciﬁc mAb E5 (dilution 1:250)
in PBS containing 5% FBS for 30 min at room temperature. After three
washes with drops of PBS for 10 min, sections were incubated for
20 min using mouse IgG speciﬁc antibody coupled to 10 nm diameter
colloidal gold particles using a 1:100 dilution in 5% FBS/PBS.
Cryosections were washed three times with drops of PBS for 10 min
and twice with distilled water. As a control for non-speciﬁc binding of
the colloidal gold-conjugated antibody, the primary antibody was
omitted. Cells were observed using a Jeol Electron Microscope (JEM
1020) with a CCD camera SIS Megaview III.
Plasma membrane protein biotinylation
Vero E6 cells were grown to 70% conﬂuency in 75 cm2 ﬂasks and
either mock transfected, or transfected with 37.5 μg of empty pcDNA
3.1 (+) or pcDNA-E plasmids using 37.5 μl of Lipofectamine 2000
(Invitrogen) according to manufacturer's instructions. In parallel,
Vero E6 cells were grown to 90% conﬂuency and infected with rSARS-
CoV-ΔE or rSARS-CoVwt at an moi of 0.3. At 24 hpt or hpi, cell surface
proteins were biotin labeled using the Cell Surface Protein Isolation
Kit (Pierce) following the manufacturer's indications. Brieﬂy, cells
were rinsed twice with ice-cold PBS, and incubated with EZ-link
Sulfo-NHS-SS-biotin for 15 min at 4 °C to biotinylate surface proteins.
Reaction was quenched, cells were washed twice with PBS and
scrapped. Cells were pelleted, lysed and cell extracts were clariﬁed by
centrifugation. Biotin labeled proteins were puriﬁed using afﬁnity
chromatography, by incubating cell extracts for 1 h with a neutravidin
Sepharose resin. Resin was washed three times, and bound proteins
were eluted by adding SDS-sample buffer.
Whole-cell patch clamp
HEK-293T cells were grown to 70% conﬂuency in 12.5 cm2 ﬂasks
and transfected with 12.5 μg of DNA using 37.5 μl of Lipofectamine
2000 (Invitrogen) according to manufacturer's indications. At 8 hpt
cells were trypsinized and seeded onto poly-L-lysine coated glass
coverslips. At 24 hpt whole-cell currents were recorded at room
temperature using an Axopatch 1D ampliﬁer (Axon instruments).
Cells were placed in a bath solution containing (in mM): 5 KCl, 135
NaCl, 1 MgCl2, 2 CaCl2, 10 Glucose, 10 HEPES, and BSA 0.001% pH 7.4
and ﬁlled through the electrode with a solution containing (in mM):
110 KCl, 5 NaCl, 0.5 CaCl2, 5 EGTA, 2 MgCl2 and 10 HEPES pH 7.2. The
voltage clamp protocol consisted of rectangular voltage steps of 40 ms
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from a holding potential of −40 mV.
Pull-down assays
Vero E6 cells were grown to 90% conﬂuence and mock infected,
infected at anmoi of 0.1 with rSARS-CoVwt or with a virus containing a
tagged E protein (rSARS-CoV-ETagCt) for further puriﬁcation of
associated protein complexes (Alvarez et al., 2010). Cell extracts,
tandem afﬁnity puriﬁcation and mass spectrometry were performed as
previously described to identify SARS-CoV E bound proteins (Alvarez
et al., 2010).
Plasma membrane selective permeabilization assays
Prior to ﬁxation, cells were placed on ice and rinsed twicewith KHM
buffer (110 mM potassium acetate, 2 mM magnesium acetate, and
20 mM HEPES pH 7.2). After that, the plasma membrane of cells was
selectively permeabilized with 25 μg/ml of digitonin (Sigma) in KHM
buffer for 5 min at 4 °C. Then, cells werewashed twicewith KHMbuffer,
ﬁxedwith 4% paraformaldehyde in PBS for 30 min at room temperature
and subjected to immunoﬂuorescence as described before.
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